EGFR‐tyrosine kinase inhibitors (EGFR‐TKIs) are the current standard of care for patients with advanced EGFR mutant (EGFRm) NSCLC, and can prolong survival significantly.11, 15. Here, EGFR is linked to non-small cell lung carcinoma.